Why would Stallicia enter into a contract with a company to acquire the rights to use its primary asset, Sulforaphane, and then not use that product in its own trials?
RE: Thousands of patients on phase 2/3 Trial2 Nov 2020 15:42
Professor James Chalmers and colleagues are running the STOP-COVID19 trial to see if a new drug, Brensocatib, can help people with COVID-19. There’s no mention of SFX 01.